| INTRODUCTION
Plantar warts are a common problem that poses a challenge to dermatologists and physicians as such. Despite the many modalities available for treating such condition yet almost 60% report failure while as much as 25% of patient seek multiple modalities. [1] [2] [3] [4] [5] [6] Bleomycin had been used since the seventies of last century for eliminating warts and despite almost six decades of use, yet reports and studies show discrepancies among cure rates that range from 0 up to 100% in certain circumstances. Blemoycin inhibits the deoxyribonucleic acid (DNA) and protein synthesis and hence can induce tissue death. 7 Different concentration techniques were used ranging from 0.1 U/mL and up to 3 U/mL and different methods for delivery of blemoycin, namely intralesional, sublesional, perilesional, and multipuncture techniques, were assessed by a number of studies with variable outcomes. 8 It is hypothesized that the reason for the large variability of cure rate is due to poor bleomycin infiltration and lack of full coverage of large areas. One main disadvantage of IL bleomycin injection is the severe pain associated with the injection. 9 To increase infiltration, area of coverage, and decrease pain associated with the IL injection, we assessed a novel minimally invasive method of combining microneedling with spraying of bleomycin and occlusion vs intralesional injection of bleomycin. An advantage of this technique is that it creates transient, aqueous pores in the outermost layer of the skin that can fortify the drug delivery and decrease pain and side effects.
| PATIENTS AND METHODS

| Patients
Sixty patients with plantar warts were enrolled into the current study. The patients were recruited from April 2017 to July 2017.
Informed written consents were obtained from all participants before approval of the ethical committees were obtained to proceed.
Patients were divided into two groups (A&B). Each group consisted of (30) patients. Group (A) subjects received intralesional bleomycin injections. For Group (B) subjects, we combined microneedling with spraying of bleomycin and this was followed by occlusion for 2 hours. Pregnant, lactating, immunosuppressed, and those patients with chronic liver disease, renal disease, and peripheral vascular disease were all ruled out of the study.
| Injection technique
Bleomycin (Bleocin, Nippon Kayaku Co. Ltd, Japan) is typically supplied in 15 U vials. The preparation was diluted first with 5 mL normal saline. Just before injection, the preparation was further diluted by adding (2 mL) of lidocaine (2%), double the amount taken from the vial, so that the concentrations become 1 U/mL (1 mg/1 mL). Overlying calluses were pared with a number 15 blade, and injections were performed every 2 weeks for a maximum of 4 sessions. A maximum of 5 warts were treated per patient in 1 session. The maximum total amount of bleomycin injected into a patient in one session was 1 U/1 mL (1 mg/mL).
In group A, bleomycin was injected into the base of the wart using an insulin syringe. Injection was continued until each wart had blanched while in group B, microneedling was performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes, followed by spraying of the prepared bleomycin on the lesion/s and then occlusion applied for 2 hours. Clinical changes or adverse reactions were recorded every 2 weeks for the 2 months of treatment and monthly thereafter. Clinical images were recorded using a HUAWEI GRA-UL10/13 mega pixel camera before treatment and every 2 weeks after the last session.
| Follow-ups
Follow-up visits were scheduled 3 months after the last session to detect recurrence. Patients were considered cleared if all warts completely resolved; patients were considered partially responsive if some of the warts remained unchanged. The treatment was considered to have failed if no response was observed in any of the lesions.
| Statistical analysis
Fisher's exact test was used to assess any difference in terms of response rate at the two timepoints between the control arm and the experimental arm. SPSS software (version 17.00, SPSS, Chicago)
was used for statistical analysis. A P-value of less than .05 was considered to indicate statistical significance.
| RESULTS
Sixty patients were recruited for the study. session, 3rd session, and 4th session. But there were highly statistical significance difference between them in 2nd session ( Table 3 ).
The relation between the size of warts and the response rate in the two studied groups showed no statistically significant difference.
Similarly, no significant association was found between the therapeutic response and previous treatment of warts in both groups.
| Adverse effects
Side effects other than pain, erythema, and transient induration were relatively infrequent. No nail changes or Raynaud's phenomenon was observed in both groups. Less pain was reported among the microneedling group which was statistically significant (Table 4 ).
| Recurrence
In this study, no recurrence was observed in any of the studied patients after the 6-month follow-up period in both groups. warts. Their clearance rates were 86.6% and 74%, respectively. 15, 16 A recent case report used a microneedling pentype device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes, with intermittent topical application of 1 U/mL bleomycin. A total of 0.2-0.5 mL of bleomycin were applied to the lesion, and 4 treatments were carried out on monthly basis. They established complete clearance to their 3 cases. 17 Tamel and Karakas-Akman reported a case which responded to multipuncture administration of bleomycin for a recalcitrant plantar wart and multipuncture technique using a higher concentration of bleomycin (3 U/mL). 18 In the current study, the warts were firstly pricked by dermapen then 1 mL of the prepared solution of bleomycin (1 mg/1 mL) was sprayed on to the wart tissue and occlusion was applied for 2 hours.
| DISCUSSION
The majority of multipuncture reports in literature were performed on small patient samples and mostly presented as case reports. The T A B L E 2 Comparison between the two studied groups regarding the size of the warts, previous modalities of treatment and current study treatment success rates Raynaud's phenomenon 0 0.0% 0 0.0% 0.000* 1.000 differences in this study population, the number of the studied patients, the sensitivity degree and concentration of bleomycin, and the number, type, duration, and resistance of warts may be responsible for the difference between the present study and other related studies on intralesional bleomycin with multiple puncture techniques.
No statistically significant association was found between the therapeutic response of both groups and the different clinical variables, including age, sex, site, size, duration, and previous therapy of warts. However, statistically significant difference was found between the two groups in the number of treatment sessions where a more rapid response and a less number of the treatment sessions were observed in the microneedling group.
Adverse effects in both groups were mild, transient, and insignificant. Pain was constant finding in all of the studied patients of group A (100%) while only (20%) of the studied patients of group B reveled pain which typically lasting 24-72 hours. It is worth mentioning that pain following single puncture injection of bleomycin into or beneath warts may persist for a week. Local reactions such as erythema and edema were frequently reported in both groups. There was no recurrence of the lesions after the 6-month follow-up period in the two groups.
Microneedling-assisted multipuncture technique has an advantage of reducing deep injection of higher concentrations of bleomycin, providing a more homeogenous distribution of the bleomycin throughout the entire wart and producing less pain as well as fewer tendencies to any adverse events.
In conclusion, intralesional bleomycin seems to be a promising effective and safe remedy for plantar warts with good cure rates and excellent safety profile and less painful with microneedling-assisted multipuncture technique. Further studies on larger populations are recommended, and long follow-up of the patients is mandatory to assess possible recurrences and to evaluate the long-term efficacy
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